This report was first published by Endpoints News. To see the original version, click here
The FDA on Friday approved Pfizer and Arvinas’ drug vepdegestrant for patients with a certain form of breast cancer. But it’s unclear how many will take it.
The drug will be branded as Veppanu, and it was the centerpiece of the companies’ collaboration for PROTAC degraders. Back in 2021, Pfizer paid $1 billion upfront to expand its development in breast cancer.
您已阅读35%（452字），剩余65%（831字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。